News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
ZOLINZA (vorinostat) in Combination with Bortezomib Demonstrated Clinical Activity
December 10, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 1
MORE ON THIS TOPIC
Cancer
Merck’s billion-dollar Kelun bet pays off as TROP2 improves survival in endometrial cancer
May 19, 2026
·
2 min read
·
Tristan Manalac
Drug Development
Is Revolution ‘the next oncology titan’? Truist analysts make the case
May 18, 2026
·
3 min read
·
Heather McKenzie
Deals
Regeneron, Parabilis set out to create new drug class in deal worth up to $2.3B
May 18, 2026
·
2 min read
·
Gabrielle Masson
Postmarket research
Amgen’s rare disease drug Tavneos tied to 20 deaths in Japan
May 18, 2026
·
2 min read
·
Tristan Manalac